Borghaei, H., Alpaugh, K., Hedlund, G., Forsberg, G., Langer, C., Rogatko, A., . . . Cohen, R. B. (2009). Phase I Dose Escalation, Pharmacokinetic and Pharmacodynamic Study of Naptumomab Estafenatox Alone in Patients With Advanced Cancer and With Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer. American Society of Clinical Oncology.
Chicago Style CitationBorghaei, Hossein, et al. Phase I Dose Escalation, Pharmacokinetic and Pharmacodynamic Study of Naptumomab Estafenatox Alone in Patients With Advanced Cancer and With Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer. American Society of Clinical Oncology, 2009.
Cita MLABorghaei, Hossein, et al. Phase I Dose Escalation, Pharmacokinetic and Pharmacodynamic Study of Naptumomab Estafenatox Alone in Patients With Advanced Cancer and With Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer. American Society of Clinical Oncology, 2009.